

	<b>DLA Piper LLP (US)</b> 4365 Executive Drive, Suite 1100 San Diego, California 92121-2133 <b>T</b> 858.677.1400 <b>F</b> 858.677.1401 <b>W</b> <a href="http://www.dlapiper.com">www.dlapiper.com</a>
<b>Facsimile</b>	Stepanek, Cynthia <b>T</b> 858.638.6677 <b>F</b>

**Date:** 6/17/2009

<b>To:</b>	<b>Phone:</b>	<b>Fax:</b>
<b>Examiner Maury A. Audet</b>		915712730960
<b>USPTO</b>		

Pages (*including fax sheet*): 5**Comments:**

US Appln No. 10/802,919

Dear Examiner Audet:

Please see the attached letter re US Application No. 10/802,919. If you have any questions or require additional information please contact us at your earliest convenience.

Please confirm receipt of this facsimile to Cynthia Stepanek ([cynthia.stepanek@dlapiper.com](mailto:cynthia.stepanek@dlapiper.com)) or (858) 638-6677.

Sincerely,  
Cynthia

**Cynthia L. Stepanek**  
Patent Assistant to Edward D. Robinson

**DLA Piper LLP (US)**  
4365 Executive Drive, Suite 1100  
San Diego, California 92121

858.638.6677 T  
858.677.1465 F  
[cynthia.stepanek@dlapiper.com](mailto:cynthia.stepanek@dlapiper.com)

---

*The information contained in this facsimile message is confidential and, if addressed to our client or certain counsel, is subject to the attorney-client or work product privilege. This message is intended only for the use of the individual or entity named above. If the reader of this message is not the intended recipient, or the employee or agent responsible to deliver it to the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please notify us immediately by telephone and return the original message to us at the above address via the U. S. Postal Service.*

6/17/2009 1:48:00 PM-ET

Stepanek, Cynthia

DLAPIPER

Page. 2

- 2 -

BALTI\_LOCAL:215.v1 3/19/02



DLA Piper LLP (US)  
4365 Executive Drive, Suite 1100  
San Diego, California 92121-2133  
[www.dlapiper.com](http://www.dlapiper.com)

Edward D. Robinson  
[ed.robinson@dlapiper.com](mailto:ed.robinson@dlapiper.com)  
T 858.677.1434  
F 858.677.1465

June 17, 2009

**Via Facsimile (S71) 273-0960**

Examiner Maury A. Audet  
United States Patent and Trademark Office  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**Re: U.S. Patent Application No. 10/802,919**  
**Entitled: METHODS FOR DELIVERING COMPOUNDS INTO A CELL**  
**Filed: March 18, 2004**  
**Inventors: Unger and McCreery**  
**Our Docket: IMARX1380-3**

Dear Examiner Audet:

Thank you for your time yesterday to discuss the Terminal Disclaimer of June 3, 2009, which was submitted to the U.S. Patent & Trademark Office in connection with the above referenced application. As we previously agreed upon, the submitted Terminal Disclaimer was provided in order to correctly identify U.S. Patent No. 6,638,767.

A review of Public PAIR has indicated that the submitted Terminal Disclaimer has not been approved because it states "IMARX THERAPEUTICS, INC." as owner of the pending application, whereas U.S. Patent Application Publication No. 2004/0176473 A1 (U.S. Application No. 10/802,919) and U.S. Patent No. 6,638,767, state "ImaRx Pharmaceutical Corp." as the owner.

As explained below, the recorded Assignments for U.S. Application No. 10/802,919 and U.S. Patent No. 6,638,767 demonstrate that the correct owner for both of these cases is "IMARX THERAPEUTICS, INC."

**U.S. Application No. 10/802,919**

The continuity data for U.S. Application No. 10/802,919 is provided below:

U.S. Application No. 10/802,919 is a divisional application of U.S. Application No. 08/841,169, now U.S. Patent No. 6,743,779; which is a continuation-in-part application of U.S. Application No. 08/785,661, now abandoned; which is a continuation-in-part application of U.S. Application

WEST21735981.1  
353840-000141



Examiner Maury A. Audet  
 June 17, 2009  
 Page Two

No. 08/640,554, now abandoned; which is a continuation of U.S. Application No. 08/346,426, now U.S. Patent No. 5,733,572.

In the case of a divisional application, a prior assignment recorded against the original application is applied to the divisional application.

The recorded Assignments for U.S. Patent Nos. 6,743,779 and 5,733,572 are outlined in the below tables:

U.S. Patent No. 6,743,779		
Assignment (Reel/Frame)	Assignors	Assignee
1 (008712/0725)	UNGER, EVAN C. MCCREERY, THOMAS	IMARX PHARMACEUTICAL CORP.
2 (011425/0046)	IMARX PHARMACEUTICAL CORP. AN ARIZONA CORPORATION	IMARX, LLC
3 (011425/0432)	IMARX, LLC	IMARX THERAPEUTICS, INC.
4 (011436/0117)	IMARX THERAPEUTICS, INC.	IMARX THERAPEUTICS, INC.
5 (017626/0618)	IMARX PHARMACEUTICAL CORPORATION	IMARX THERAPEUTICS, INC.

U.S. Patent No. 5,733,572		
Assignment (Reel/Frame)	Assignors	Assignee
1 (007569/0991)	UNGER, EVAN C. MATSUMAGE, TERRY YELLOWHAIR, DAVID	IMARX PHARMACEUTICAL CORP.
2 (011425/0046)	IMARX PHARMACEUTICAL CORP. AN ARIZONA CORPORATION	IMARX, LLC
3 (011425/0432)	IMARX, LLC	IMARX THERAPEUTICS, INC.
4 (011436/0117)	IMARX THERAPEUTICS, INC.	IMARX THERAPEUTICS, INC.
5 (011497/0505)	IMARX THERAPEUTICS, INC.	SILICON VALLEY BANK
6 (015592/0901)	SILICON VALLEY BANK	IMARX THERAPEUTICS, INC.
7 (017626/0618)	IMARX PHARMACEUTICAL CORPORATION	IMARX THERAPEUTICS, INC.



Examiner Maury A. Audet  
 June 17, 2009  
 Page Three

As evidenced by their recorded Assignments, both U.S. Patent Nos. 6,743,779 and 5,733,572 are owned by IMARX THERAPEUTICS, INC. In addition, from the continuity data outlined above, U.S. Application No. 10/802,919 is also owned by IMARX THERAPEUTICS, INC.

**U.S. Patent No. 6,638,767**

The recorded Assignments for U.S. Patent No. 6,638,767 are outlined in the below table:

U.S. Patent No. 6,638,767		
Assignment (Reel/Frame)	Assignors	Assignee
1 (011396/0421)	UNGER, EVAN C. MCCREERY, THOMAS	IMARX PHARMACEUTICAL CORPORATION
2 (017626/0618)	IMARX PHARMACEUTICAL CORPORATION	IMARX THERAPEUTICS, INC.

As evidenced by their recorded Assignments, U.S. Patent No. 6,638,767 is also owned by IMARX THERAPEUTICS, INC.

In conclusion, it is submitted that the Terminal Disclaimer of June 3, 2009, names the correct owner for U.S. Application No. 10/802,919 and U.S. Patent No. 6,638,767, namely: "IMARX THERAPEUTICS, INC."

It is our understanding that with this clarification of the ownership, this application is now in condition to be issued.

If you have any questions or require additional information, please contact us at your earliest convenience.

Very truly yours,

**DLA Piper LLP (US)**

A handwritten signature in black ink, appearing to read 'Edward D. Robinson'.

Edward D. Robinson  
 Associate

EDR:cls

cc: Lisa A. Haile, J.D., Ph.D. – DLA Piper LLP (US)

WEST21735981.1  
 353840-000141